These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 21518843)

  • 1. Transcriptional profiling of azole-resistant Candida parapsilosis strains.
    Silva AP; Miranda IM; Guida A; Synnott J; Rocha R; Silva R; Amorim A; Pina-Vaz C; Butler G; Rodrigues AG
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3546-56. PubMed ID: 21518843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical azole cross-resistance in Candida parapsilosis is related to a novel MRR1 gain-of-function mutation.
    Branco J; Ryan AP; Pinto E Silva A; Butler G; Miranda IM; Rodrigues AG
    Clin Microbiol Infect; 2022 Dec; 28(12):1655.e5-1655.e8. PubMed ID: 36028086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upc2-mediated mechanisms of azole resistance in
    Li J; Aubry L; Brandalise D; Coste AT; Sanglard D; Lamoth F
    Microbiol Spectr; 2024 Feb; 12(2):e0352623. PubMed ID: 38206035
    [No Abstract]   [Full Text] [Related]  

  • 4. Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles.
    Pinto e Silva AT; Costa-de-Oliveira S; Silva-Dias A; Pina-Vaz C; Rodrigues AG
    FEMS Yeast Res; 2009 Jun; 9(4):626-33. PubMed ID: 19385998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ERG3 mutations and expression of ergosterol genes controlled by UPC2 and NDT80 in Candida parapsilosis azole resistance.
    Branco J; Ola M; Silva RM; Fonseca E; Gomes NC; Martins-Cruz C; Silva AP; Silva-Dias A; Pina-Vaz C; Erraught C; Brennan L; Rodrigues AG; Butler G; Miranda IM
    Clin Microbiol Infect; 2017 Aug; 23(8):575.e1-575.e8. PubMed ID: 28196695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazole Evolution of Candida parapsilosis Results in Cross-Resistance to Other Antifungal Drugs, Influences Stress Responses, and Alters Virulence in an Antifungal Drug-Dependent Manner.
    Papp C; Bohner F; Kocsis K; Varga M; Szekeres A; Bodai L; Willis JR; Gabaldón T; Tóth R; Nosanchuk JD; Vágvölgyi C; Gácser A
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33115837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Transcriptomics Approach To Unveiling the Mechanisms of
    Cavalheiro M; Costa C; Silva-Dias A; Miranda IM; Wang C; Pais P; Pinto SN; Mil-Homens D; Sato-Okamoto M; Takahashi-Nakaguchi A; Silva RM; Mira NP; Fialho AM; Chibana H; Rodrigues AG; Butler G; Teixeira MC
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348666
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals.
    Eddouzi J; Parker JE; Vale-Silva LA; Coste A; Ischer F; Kelly S; Manai M; Sanglard D
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3182-93. PubMed ID: 23629718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris.
    Li J; Coste AT; Bachmann D; Sanglard D; Lamoth F
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0006722. PubMed ID: 35343781
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Nishimoto AT; Wiederhold NP; Flowers SA; Zhang Q; Kelly SL; Morschhäuser J; Yates CM; Hoekstra WJ; Schotzinger RJ; Garvey EP; Rogers PD
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D; Coste AT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination.
    Castanheira M; Deshpande LM; Messer SA; Rhomberg PR; Pfaller MA
    Int J Antimicrob Agents; 2020 Jan; 55(1):105799. PubMed ID: 31520783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Zinc Cluster Transcription Factor Contributes to the Intrinsic Fluconazole Resistance of Candida auris.
    Mayr EM; Ramírez-Zavala B; Krüger I; Morschhäuser J
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32321822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species distribution, azole resistance and related molecular mechanisms in invasive Candida parapsilosis complex isolates: Increase in fluconazole resistance in 21 years.
    Demirci-Duarte S; Arikan-Akdagli S; Gülmez D
    Mycoses; 2021 Aug; 64(8):823-830. PubMed ID: 33934400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virulence factors, antifungal susceptibility and molecular mechanisms of azole resistance among Candida parapsilosis complex isolates recovered from clinical specimens.
    Neji S; Hadrich I; Trabelsi H; Abbes S; Cheikhrouhou F; Sellami H; Makni F; Ayadi A
    J Biomed Sci; 2017 Sep; 24(1):67. PubMed ID: 28870262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland.
    Szweda P; Gucwa K; Romanowska E; Dzierz Anowska-Fangrat K; Naumiuk Ł; Brillowska-Da Browska A; Wojciechowska-Koszko I; Milewski S
    J Med Microbiol; 2015 Jun; 64(6):610-619. PubMed ID: 25818698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
    Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
    Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.
    Sanati H; Belanger P; Fratti R; Ghannoum M
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2492-6. PubMed ID: 9371355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.